In the case of targeted delivery of ruthenium and gold complexes into cancer cells, the reported studies targeting the GFR mainly focus on the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and fibroblast growth factor receptor (FGFR), all three being RTK as well. Here, EGFR is linked to cancer.